Dynamic Medical Solutions LLC’s Post

Robotic-Assisted Partial Nephrectomy (RAPN) represents a groundbreaking approach to kidney cancer treatment. Unlike traditional surgeries that often necessitate the removal of the entire kidney, RAPN enables the precise excision of only the cancerous portion while sparing the majority of healthy tissue. This meticulous procedure not only eradicates the tumor but also safeguards crucial kidney function, as it minimizes damage to the remaining organ. Using state-of-the-art robotic technology, surgeons can navigate with unparalleled accuracy, ensuring optimal outcomes for patients. The robotic system provides enhanced visualization and dexterity, allowing surgeons to perform intricate maneuvers with precision. Additionally, RAPN offers numerous benefits over conventional open surgery, including smaller incisions, reduced blood loss, shorter hospital stays, and quicker recovery times. By preserving as much healthy kidney tissue as possible, RAPN minimizes the risk of post-operative complications and enhances the patient's quality of life. This innovative approach represents a significant advancement in kidney cancer care, offering hope to patients and their families. As the field of robotic surgery continues to evolve, RAPN stands as a testament to the power of technology in improving patient outcomes and revolutionizing medical treatment. #RoboticSurgery #KidneyCancerAwareness #InnovativeTreatment #HealthcareRevolution

Detection-2 Feasibility study now open at hospitals across the UK! The Detection-2 study is looking at using a ctDNA blood test to guide treatment for patients with high-risk stage 2B/2C/3A cutaneous melanoma who have had surgery to remove it. For more information about the study, view our Melanoma TrialFinder:https://buff.ly/4gLpwnB You can also view the Detection-2 video: https://buff.ly/3DAdzT9 Detection-2 feasibility study will be open for 1 year in at least 8 centres across the UK. Keep up to date with our Find a Trial tool to know which centres/hospitals are open in real time. Find a Trial Tool: https://buff.ly/3SC5tM9 #melanoma #melanomatrial #trialfinder #clinicaltrials

Congrats to the Lumicell team on their FDA approval! This marks a significant moment in the company's history and a major milestone in our mission to revolutionize the paradigm of cancer surgery. Breast cancer ranks as the second leading cause of death among women, with a 1 in 8 risk of diagnosis. Up to 40% of patients experience cancer recurrence due to residual cancer cells. Powered by a Nobel Prize winning team and technology, Lumicell is on the mission to dramatically change the face of surgical oncology so that outcomes during cancer surgery are dramatically improved. Lumicell previously received FDA Fast Track and Breakthrough Device designations for its innovative technology. With the FDA’s historic approval, LumiSystem is now the first and only imaging combination product capable of detecting cancer where it matters most, inside the breast cavity. With 84% diagnostic accuracy, LumiSystem enables surgeons to scan the breast cavity post-lumpectomy, in real-time, to detect and resect residual cancer that may have otherwise been missed. Surgeons can use Lumicell's imaging platform to detect and remove cancer, cell by cell. #HealthcareInnovation #FDAapproval #CancerSurgery

BREAKING NEWS:  LUMISIGHT™ and Lumicell™ DVS are FDA-approved, and together are referred to as LumiSystem™. With 84% diagnostic accuracy, LumiSystem enables surgeons to scan the breast cavity post-lumpectomy, in real-time, to detect and resect residual cancer that may have otherwise been missed, potentially sparing some patients from second surgeries. 1-2  The most common side effects with LUMISIGHT are hypersensitivity and an abnormal color in urine. LUMISIGHT may cause serious hypersensitivity reactions, including anaphylaxis. Read our release here: https://bit.ly/4cXkvqR Please see the LUMISIGHT Prescribing Information (https://bit.ly/440dAZK), including Boxed Warning, and Lumicell DVS Instructions for Use (https://bit.ly/3Q78nK9).  For complete product information, visit www.LumiSystem.com.  1. Diagnostic accuracy is based on true positive and true negative images detected in the LumiSystem pivotal trial   2. Smith, et al.,  NEJM Evidence 2023; 2(7) #FDA-Approved #LUMISIGHT, #LumicellDVS, #LumiSystem, #Lumicell

What is a CT scan? Computed Tomography (CT) scans create detailed two or three dimensional images of your organs, bones, or tissues using computer processing and X-Rays taken from various angles. A CT scan has many uses. It's used to diagnose disease or injury as well as to plan medical, surgical or radiation treatment. Your doctor may suggest a CT scan for many reasons. For instance, a CT scan can help: o  Diagnose muscle and bone conditions, such as bone tumors and breaks, also called fractures. o  Show where a tumor, infection or blood clot is. o  Guide procedures such as surgery, biopsy and radiation therapy. o  Find and watch the progress of diseases and conditions such as cancer, heart disease, lung nodules and liver masses. o  Watch how well certain treatments, such as cancer treatment, work. o  Find injuries and bleeding inside the body that can happen after trauma. #Teachingthursdays #CTscan #Learning #Mqn Sources: https://lnkd.in/dx5gYN6 https://lnkd.in/g7uGK7hJ

Repeat breast cancer surgeries can be physically and emotionally draining. This US study highlights how important it is to get it right the first time. Using Patient Reported Outcomes (PROs), researchers assessed how re-excisions and tissue removal affected breast satisfaction and wellbeing for patients over three years following surgery. Their findings are clear: minimising re-excisions and reducing the volume of healthy tissue removed are vital for improving patient outcomes, both physically and psychologically. At OncoRes Medical, we're developing innovative technology to address this very need. Our goal is to empower surgeons with enhanced precision, potentially leading to fewer repeat surgeries, preservation of healthy breast tissue, and a more positive experience for patients. Read the study 👉  https://lnkd.in/gNYbmPRw #OncoRes #medtech #innovation #breastcancer #breastconservation #breastconservationsurgery #lumpectomy #patientsfirst #patientoutcomes

📜Today we share the #Review "Role of Endoscopic Ultrasound-Guided Radiofrequency Ablation in Pancreatic Lesions: Where Are We Now and What Does the Future Hold?" 🔗Link here: https://lnkd.in/d4d492Z2 👥by Radhika Chavan et al. 🔆Endoscopic ultrasound (EUS) is a minimally invasive and effective option for high-risk pancreatic tumor patients or those who refuse surgery. Radiofrequency ablation (RFA) uses high-frequency currents to induce coagulative necrosis of the tumor and also offers immunomodulatory benefits. EUS enables precise tumor localization, assesses size, vascularity and adjacent structures, and also guides targeted treatment. Multiple studies have showed utility and effectiveness of EUS-RFA in managing insulinomas and non-functional neuroendocrine tumors (NETs). This review covers RFA devices, techniques, outcomes, and future directions, emphasizing its potential in treating various pancreatic tumor including NET, cystic lesions, and adenocarcinomas. Key studies on role of EUS-RFA in these pancreatic tumor are discussed in details🔆

MV MRS for Glioblastoma from #Fujifilm Echelon smart Case study with altered CHO / CR and CHO/NAA ratios Increased Lipid / lactate MRS As Non Invasive method is a suitable technique used to diagnosis of GBM (glioblastoma mltiforme) Tr providing anatomical visualization of brain Tr. In MRI Images GBM is seen as ring enhancing lesions. However the pattern is not exclusive to GBM .and is present in other diseases such as Tumefactive ,multiplesclerosis, abscess,and mets.Inspite of high contrast of soft tissue in MRI images for GBM tumor site, spatial spread of cerebral Malignant cells is not detectable with MR modalities. Distinction between healthy and tumoral areas are critical for Treatment process including surgery,chemotherapy or radiotherapy. Ref.PMCID:PMC7229458 Meyam Siyah Mansoory Ph.D MRS ,P.C 3D sequences and routine sequences acquisition credit to Indhu V - Senior MR Application Specialist Fujifilm Acquisition Time : Post contrast 3D T1 RSSG -2.40sec Sag T2 FSE -1 Min.

Cape Cod Healthcare has taken an innovative leap forward in lung cancer detection. We’re pleased to announce that thoracic surgeon Dr. Jeff Spillane (left in photo) and interventional pulmonologist Dr. Michael Ayers (right) performed the first Ion Robotic Bronchoscopy procedure at Cape Cod Hospital this week! Ion offers exceptional precision, navigating deep into the lungs and allowing physicians to reach small, hard-to-access lung nodules. Paired with a 3D map of a patient's low dose CT scan, this real-time biopsy method enables earlier and more accurate diagnoses — all without invasive surgery or needle punctures. To learn more, visit www.capecodhealth.org/ion #LungCancerAwareness #EarlyDetection #Innovation #Milestones

Study Finds Better Organ Preservation with Long-Course Radiotherapy in Rectal Cancer 🔗 https://bit.ly/3XF7cFT “The crucial knowledge gaps were whether organ preservation is safe after SCRT and which radiation treatment is best if organ preservation is the goal. Until now, there were no studies comparing SCRT and long course of chemoradiotherapy, LCCRT, in terms of organ preservation and local regrowth rates. Our study is the first to address both, finding that organ preservation by avoiding surgery after neoadjuvant SCRT is safe and may be preferred for some patients due to the convenience of treatment. However, the tumor regrowth rate was higher, necessitating close monitoring. If time and convenience aren’t factors, LCCRT appears to offer more durable organ preservation.”